Kazia Therapeutics Declares a Private Placement of $2 Million, Priced Above Market Rates
Kazia Therapeutics Limited, an oncology-focused drug development company, has announced a private placement of equity securities (PIPE) worth approximately $2 million. The deal, expected to close on August 4, 2025, subject to customary closing conditions, involves the sale of ordinary shares and pre-funded warrants to established institutional investors at a 5% premium to the closing price of Kazia’s ADSs on July 31, 2025.
The private investment in public equity (PIPE) is a straightforward equity investment with no common warrant coverage. After deducting estimated offering expenses, Kazia expects to net approximately $2 million in proceeds. The company intends to use these funds to support the continued clinical development of its lead drug candidates.
One of the key candidates is paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in trials for brain cancer and advanced breast cancer. Another is EVT801, a selective VEGFR3 inhibitor. The net proceeds will also be used for general corporate purposes.
Detailed risk factors associated with the transaction are described in Kazia’s Annual Report and subsequent SEC filings. It is important to note that risk factors that could cause actual results to differ from forward-looking statements include those related to market and other conditions, clinical and preclinical trials, regulatory approvals, and global economic conditions.
The Company undertakes no obligation to publicly update any forward-looking statement, except as required under applicable law. Preliminary or interim data may not reflect final results in the context of clinical and preclinical trials.
For investor and media inquiries, please contact Alex Star at [email protected] or +1-201-786-8795.
[1] Kazia Therapeutics Limited. (2025, August 1). Kazia Therapeutics Limited Announces Definitive Agreement for Private Placement of Equity Securities. Business Wire. [2] Kazia Therapeutics Limited. (2025, August 1). Kazia Therapeutics Limited Announces Private Placement of Equity Securities. GlobeNewswire. [3] Kazia Therapeutics Limited. (n.d.). About Kazia. Retrieved from https://www.kazia.com.au/about-us/ [4] Kazia Therapeutics Limited. (n.d.). Paxalisib. Retrieved from https://www.kazia.com.au/pipeline/paxalisib/ [5] Kazia Therapeutics Limited. (n.d.). EVT801. Retrieved from https://www.kazia.com.au/pipeline/evt801/ [6] Kazia Therapeutics Limited. (n.d.). Risk Factors. Retrieved from https://www.sec.gov/Archives/edgar/data/1591399/000119312520104474/d27988dex11.htm [7] Kazia Therapeutics Limited. (n.d.). Forward-Looking Statements. Retrieved from https://www.kazia.com.au/investors/news-and-events/forward-looking-statements/
Investors may consider the private placement of equity securities by Kazia Therapeutics Limited, worth approximately $2 million, as a potential investment opportunity for financing the company's continued clinical development of its lead drug candidates, such as paxalisib and EVT801. However, potential investors should carefully evaluate risk factors, including market conditions, trial results, regulatory approvals, and global economic conditions, as detailed in Kazia's Annual Report and SEC filings.
